The Use of CRISPR/Cas9 Technology in Engineering Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy for the Treatment of Cancer in Brazil

被引：0
|
作者：
Carvalho, Julia [1 ]
Cupello, Mauricio [2 ]
Medina, Romulo [2 ]
机构：
[1] INCA, Rio De Janeiro, Brazil
[2] Unigranrio, Rio De Janeiro, Brazil
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CAR-T; CRISPR/Cas9; Brazil; gene editing; universal CAR-T cells;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT-312
引用
收藏
页码：S525 / S526
页数：2
相关论文
共 50 条
  • [31] Universal allogeneic CAR-T cells engineered with Sleeping Beauty transposons and CRISPR/Cas9 for cancer immunotherapy
    Tipanee, J.
    Samara-Kuko, E.
    Gevaert, T.
    Chuah, M. K.
    VandenDriessche, T.
    HUMAN GENE THERAPY, 2022, 33 (23-24) : A124 - A124
  • [32] Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer
    Kavousinia, Pegah
    Ahmadi, Mohammad Hossein
    Sadeghian, Hamid
    Bafghi, Mahdi Hosseini
    CYTOTHERAPY, 2024, 26 (05) : 436 - 443
  • [33] Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer
    Li, Feng
    Zhang, Tengfei
    Cao, Ling
    Zhang, Yi
    CURRENT STEM CELL RESEARCH & THERAPY, 2018, 13 (05) : 327 - 335
  • [34] Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas
    Huang, Xin
    Greene, Joseph
    Pao, James
    Mulvey, Erin
    Zhou, Sophia X.
    Sachdev, Deepali
    Yee, Douglas
    Rader, Christoph
    Albert, Catherine M.
    Park, Haein
    Chu, Yaya
    Hamby, Carl
    Loeb, David
    Cairo, Mitchell S.
    Zhou, Xianzheng
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S184 - S185
  • [35] Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies
    Maganti, Harinad B.
    Kirkham, Aidan M.
    Bailey, Adrian J. M.
    Shorr, Risa
    Kekre, Natasha
    Pineault, Nicolas
    Allan, David S.
    CYTOTHERAPY, 2022, 24 (04) : 405 - 412
  • [36] CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
    Lauren Giuffrida
    Kevin Sek
    Melissa A. Henderson
    Junyun Lai
    Amanda X. Y. Chen
    Deborah Meyran
    Kirsten L. Todd
    Emma V. Petley
    Sherly Mardiana
    Christina Mølck
    Gregory D. Stewart
    Benjamin J. Solomon
    Ian A. Parish
    Paul J. Neeson
    Simon J. Harrison
    Lev M. Kats
    Imran G. House
    Phillip K. Darcy
    Paul A. Beavis
    Nature Communications, 12
  • [37] CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
    Giuffrida, Lauren
    Sek, Kevin
    Henderson, Melissa A.
    Lai, Junyun
    Chen, Amanda X. Y.
    Meyran, Deborah
    Todd, Kirsten L.
    Petley, Emma, V
    Mardiana, Sherly
    Molck, Christina
    Stewart, Gregory D.
    Solomon, Benjamin J.
    Parish, Ian A.
    Neeson, Paul J.
    Harrison, Simon J.
    Kats, Lev M.
    House, Imran G.
    Darcy, Phillip K.
    Beavis, Paul A.
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [38] CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence
    Wei, Wei
    Chen, Zhi-Nan
    Wang, Ke
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (15)
  • [39] Engineering the mouse genome using CRISPR/Cas9 technology
    Mianne, Joffrey
    Caulder, Adam
    Codner, Gemma
    King, Ruairidh
    Fell, Rachel
    Maritati, Marina
    Allan, Alasdair
    Jarrold, James
    Fray, Martin
    Gardiner, Wendy
    Wells, Sara
    Teboul, Lydia
    TRANSGENIC RESEARCH, 2016, 25 (02) : 251 - 251
  • [40] CRISPR/Cas9 technology in the modeling of and treatment of mucopolysaccharidosis
    Reyhani-Ardabili, Mehran
    Ghafouri-Fard, Soudeh
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2024, 39
12345